ストックスクリーナーアプリを入手
0.4053
9.35%
-0.0418
前日終値:
$0.4471
開ける：
$0.44
24時間の取引高:
8.58M
Relative Volume:
1.67
時価総額：
$112.59M
収益：
$2.02M
当期純損益:
$-97.59M
株価収益率:
-0.7052
EPS:
-0.5747
ネットキャッシュフロー:
$-102.38M
1週間 パフォーマンス:
-22.28%
1か月 パフォーマンス:
-30.00%
6か月 パフォーマンス:
-33.23%
1年 パフォーマンス:
-75.29%
1日の値動き範囲:
$0.391
$0.449
1週間の範囲:
$0.391
$0.5223
52週間の値動き範囲:
$0.391
$1.895
Humacyte Inc Stock (HUMA) Company Profile
名前
Humacyte Inc
セクター
電話
919-313-9633
住所
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.4053 | 112.59M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-07 | 開始されました | Barclays | Equal Weight |
| 2025-08-27 | 開始されました | Barclays | Overweight |
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-14 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-05-16 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 開始されました | Cowen | Outperform |
| 2021-09-24 | 開始されました | Oppenheimer | Outperform |
| 2021-09-22 | 開始されました | BTIG Research | Buy |
| 2021-09-16 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Humacyte Inc (HUMA) 最新ニュース
Humacyte Director Paul Brian Kuznik Receives 125,000 Stock Options with $0.478 Exercise Price - Kalkine Media
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - Zacks Investment Research
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
Humacyte Director D. Scott Coward Files Form 3 Reporting No Beneficial Ownership - Kalkine Media
Humacyte, Inc.Common Stock (NQ: HUMA - The Chronicle-Journal
Humacyte (NASDAQ: HUMA) director now holds 50,000 shares - Stock Titan
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Humacyte CEO to speak in New York on Sept. 16 - Stock Titan
Hospitals can keep an emergency blood-vessel graft for 36 months, up from 18 - Stock Titan
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc. Warrant (HUMAW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Humacyte Inc. Warrant (HUMAW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
HC Wainwright raises Humacyte price target to $4 - scanx.trade
Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq - Stock Titan
Humacyte Inc. Warrant (HUMAW) Peer Comparison – Compare with Others - Value Research
Humacyte plans November FDA filing for dialysis access use By Investing.com - Investing.com Nigeria
Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data - Quiver Quantitative
Humacyte plans November FDA filing for dialysis access use - investing.com
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds. - Pluang
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Morningstar
Humacyte ATEV shows superiority in Phase 3 V012 study - scanx.trade
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo
Humacyte (HUMA) Shares: Records a 7.28% Decrease to $0.68 on the Day; Next Session - vinanet.vn
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Quiver Quantitative
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.25 - Moomoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Australia
Humacyte publishes Phase 3 trial results in Lancet journal - Investing.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Canada
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com India
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
MSN Money - MSN
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Canada
Humacyte Inc (HUMA) 財務データ
収益
当期純利益
現金流量
EPS
Humacyte Inc (HUMA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jones Keith Anthony | Director |
Aug 20 '26 |
Buy |
0.69 |
10,000 |
6,930 |
40,000 |
| Jones Keith Anthony | Director |
Aug 17 '26 |
Buy |
0.59 |
30,000 |
17,820 |
30,000 |
| Sebelius Kathleen | Director |
May 19 '26 |
Buy |
0.88 |
56,818 |
50,000 |
148,025 |
| Constantino Michael T. | Director |
May 18 '26 |
Buy |
0.89 |
11,000 |
9,840 |
43,950 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
267,213 |
| Parikh Shamik J | Chief Medical Officer |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
272,713 |
| Sander Dale A. | Officer |
May 18 '26 |
Proposed Sale |
0.90 |
45,887 |
41,147 |
0 |
| Parikh Shamik J | Officer |
May 18 '26 |
Proposed Sale |
0.90 |
45,887 |
41,147 |
0 |
1.64%
0.29%
大文字化:
|
ボリューム (24 時間):